EUVIMEDEUVIMED entdecken
Crossref

Prevalence and risk factors for metabolic dysfunction-associated steatotic liver disease and fibrosis in recently diagnosed type 2 diabetes

Astrid Ruiz-Margáin, Oscar Manuel Fierro-Angulo, José Alberto González-Regueiro, Sergio Cesar Hernández-Jiménez, Ana Cristina García-Ulloa, Victoria Landa-Anell, Fernando Bril, Berenice Montserrat Roman-Calleja, Regina Romo-Arellano, Ariana Pereira-García, Naga Chalasani, Ricardo Ulises Macías-Rodríguez

World Journal of Hepatology · 27.08.2026 · 18 (8)

DOI: 10.4254/wjh.123278 ↗

Kurz gefasst

Fachartikel in der Zeitschrift World Journal of Hepatology, online erschienen am 27.08.2026. Verfasst von Astrid Ruiz-Margáin und 11 weiteren Autor:innen. Die Arbeit nennt 28 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease and the leading cause of liver-related mortality. Long-standing type 2 diabetes mellitus (T2DM) is a major risk factor for liver steatosis and fibrosis; however, whether recently diagnosed T2DM carries the same risk remains unclear. Few studies have addressed this question in Hispanic populations, who are known to exhibit faster progression of liver disease. AIM To assess the prevalence of MASLD and liver fibrosis in patients with recent-onset T2DM and to identify associated risk factors. METHODS This was a cross-sectional study including individuals with T2DM diagnosed within the past 5 years and without disabling micro or macrovascular complications. Clinical, biochemical, liver stiffness measurement (LSM), controlled attenuation parameter (CAP), and FibroScan-AST (FAST) score were evaluated. RESULTS One thousand one hundred and thirty-seven patients were included, 60.9% were women, median age was 55 years (inter quartile range: 49-63) and 78.2% were overweight or obese. Overall prevalence of MASLD (using the > 288 dB/m cutoff) was 41.4%, and 10% had clinically significant liver fibrosis (LSM ≥ 8 kPa). Moreover, 3% of the population had cirrhosis. Multivariate analysis showed higher body mass index (BMI), glycated hemoglobin, triglycerides and alanine aminotransferase (ALT) were independently associated with steatosis, while higher BMI, CAP, gamma-glutamyl transferase, ALT and aspartate aminotransferase were associated with fibrosis. According to the FAST score, 4.8% of patients had at-risk metabolic dysfunction-associated steatohepatitis. CONCLUSION There is a high burden of MASLD and clinically significant fibrosis among adults with recently diagnosed T2DM. These findings strongly support the systematic evaluation for MASLD and liver fibrosis in this population from the time of diabetes diagnosis.

Zitieren

APA

Ruiz-Margáin, A., Fierro-Angulo, O. M., González-Regueiro, J. A., Hernández-Jiménez, S. C., García-Ulloa, A. C., Landa-Anell, V., Bril, F., Roman-Calleja, B. M., Romo-Arellano, R., Pereira-García, A., Chalasani, N., & Macías-Rodríguez, R. U. (2026). Prevalence and risk factors for metabolic dysfunction-associated steatotic liver disease and fibrosis in recently diagnosed type 2 diabetes. World Journal of Hepatology, 18(8). https://doi.org/10.4254/wjh.123278

Vancouver

Ruiz-Margáin A, Fierro-Angulo OM, González-Regueiro JA, Hernández-Jiménez SC, García-Ulloa AC, Landa-Anell V, et al. Prevalence and risk factors for metabolic dysfunction-associated steatotic liver disease and fibrosis in recently diagnosed type 2 diabetes. World Journal of Hepatology. 2026;18(8). doi:10.4254/wjh.123278

BibTeX
@article{RuizMargin2026,
  author = {Ruiz-Margáin, Astrid and Fierro-Angulo, Oscar Manuel and González-Regueiro, José Alberto and Hernández-Jiménez, Sergio Cesar and García-Ulloa, Ana Cristina and Landa-Anell, Victoria and Bril, Fernando and Roman-Calleja, Berenice Montserrat and Romo-Arellano, Regina and Pereira-García, Ariana and Chalasani, Naga and Macías-Rodríguez, Ricardo Ulises},
  title = {Prevalence and risk factors for metabolic dysfunction-associated steatotic liver disease and fibrosis in recently diagnosed type 2 diabetes},
  journal = {World Journal of Hepatology},
  year = {2026},
  volume = {18},
  number = {8},
  doi = {10.4254/wjh.123278}
}
Kostenlos starten →